Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them
Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.
1. A method for inhibiting protein kinase activity of a kinase selected from the group consisting of cdk2/cyclin A, E, B1, D1, MAPK, EGFR, PKA, Cdk5/p25, IGF1-R, Aurora-2 or Cdc7/dbf4, ACK1, BRK, JAK2, MELK MPS1, NEK6, PDGFR, PDK1, PLK1, RET, ABL, AKT1, AKT2, AKT3, AUR2, IGFR1, IR, LCK, and combinations thereof, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I)
wherein R is selected from the group consisting of —R a , —COR a , —CONR a R b , —SO 2 R a or —COOR a ;
R 1 is a group —NR c R d or —OR c ;
wherein R a , R b , R c and R d , are the same or different, and are each independently hydrogen or a group optionally further substituted, selected from straight or branched C 1 -C 6 alkyl, C 2 -C 6 straight or branched alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl or cycloalkyl C 1 -C 6 alkyl, aryl or aryl C 1 -C 6 alkyl, or heterocycle or heterocycle C 1 -C 6 alkyl or, taken together with the nitrogen atom to which they are bonded, either R a and R b as well as R c and R d can form an optionally substituted 4 to 7 membered heterocycle, optionally containing one additional ring heteroatom or heteroatomic group selected from S, O, N or NH;
or isomers, tautomers or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.
3. The method according to claim 1 wherein the mammal in need thereof is a human.
4. A method for inhibiting protein kinase activity of a kinase selected from the group consisting of cdk2/cyclin A, E, B1, D1, MAPK, EGFR, PKA, Cdk5/p25, IGF1-R, Aurora-2 or Cdc7/dbf4, ACK1, BRK, JAK2, MELK, MPS1, NEK6, PDGFR, PDK1, PLK1, RET, ABL, AKT1, AKT2, AKT3, AUR2, IGFR1, IR, LCK, and combinations thereof, which comprises administering to a mammal in need thereof an effective amount of a composition comprising two or more compounds of formula (I)
wherein R is selected from the group consisting of —R a , —COR a , —CONR a R b , —SO 2 R a or —COOR a ;
R 1 is a group —NR c R d or —OR c ;
wherein R a , R b , R c and R d , are the same or different, and are each independently hydrogen or a group optionally further substituted, selected from straight or branched C 1 -C 6 alkyl, C 2 -C 6 straight or branched alkenyl, straight or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl or cycloalkyl C 1 -C 6 alkyl, aryl or aryl C 1 -C 6 alkyl, or heterocycle or heterocycle C 1 -C 6 alkyl or, taken together with the nitrogen atom to which they are bonded, either R a and R b as well as R c and R d can form an optionally substituted 4 to 7 membered heterocycle, optionally containing one additional ring heteroatom or heteroatomic group selected from S, O, N or NH;
or isomers, tautomers or a pharmaceutically acceptable salt thereof.